tradingkey.logo
tradingkey.logo
Suchen

Myriad Genetics Inc

MYGN
Zur Watchlist hinzufügen
5.990USD
-0.010-0.17%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
565.46MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Myriad Genetics Inc Unternehmen

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Inc Informationen

BörsenkürzelMYGN
Name des UnternehmensMyriad Genetics Inc
IPO-datumOct 06, 1995
CEORaha (Samraat S)
Anzahl der mitarbeiter2700
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse322 North 2200 West
StadtSALT LAKE CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl84116
Telefon18015843600
Websitehttps://myriad.com/
BörsenkürzelMYGN
IPO-datumOct 06, 1995
CEORaha (Samraat S)

Führungskräfte von Myriad Genetics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
59.05K
+8.47%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
21.32K
-1299.87%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Myriad Genetics Inc?

Die fünf größten Anteilseigner von Myriad Genetics Inc sind: Mr. Mark S. Verratti

Wie viele Institutionen halten Anteile an Myriad Genetics Inc (MYGN)?

Mit Stand vom 2026Q1 halten 539 Institutionen Anteile an Myriad Genetics Inc, mit einem Gesamtmarktwert von etwa 102.95M, was 109.00% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -7290509.00 gestiegen.

Was ist die größte Einnahmequelle von Myriad Genetics Inc?

Am 2026Q1 erzielte das Geschäft mit Hereditary Cancer für Myriad Genetics Inc den höchsten Umsatz in Höhe von 372.40M, was 45.17% des Gesamtumsatzes entspricht.